Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Cord Blood Sample Screening for Evidence of Maternal Chagas Disease.

Montgomery SP, Stramer SL.

Emerg Infect Dis. 2017 Apr;23(4):722-723. doi: 10.3201/eid2304.161287. Epub 2017 Apr 15. No abstract available.

2.

Differential Effects of Two Widely Used Solvents, DMSO and Ethanol, on the Growth and Recovery of Trypanosoma cruzi Epimastigotes in Culture.

Cevallos AM, Herrera J, López-Villaseñor I, Hernández R.

Korean J Parasitol. 2017 Feb;55(1):81-84. doi: 10.3347/kjp.2017.55.1.81. Epub 2017 Feb 28.

3.
4.

"I Cannot Be Worried": Living with Chagas Disease in Tropical Bolivia.

Forsyth CJ.

PLoS Negl Trop Dis. 2017 Jan 18;11(1):e0005251. doi: 10.1371/journal.pntd.0005251. eCollection 2017 Jan.

5.

Chagas disease research and development: Is there light at the end of the tunnel?

Chatelain E.

Comput Struct Biotechnol J. 2016 Dec 14;15:98-103. doi: 10.1016/j.csbj.2016.12.002. eCollection 2017. Review.

6.

Autochthonous Transmission of Trypanosoma Cruzi in Southern California.

Hernandez S, Flores CA, Viana GM, Sanchez DR, Traina MI, Meymandi SK.

Open Forum Infect Dis. 2016 Dec 20;3(4):ofw227. doi: 10.1093/ofid/ofw227. eCollection 2016 Oct.

7.

Chagas' heart disease: gender differences in myocardial damage assessed by cardiovascular magnetic resonance.

Assunção AN Jr, Jerosch-Herold M, Melo RL, Mauricio AV, Rocha L, Torreão JA, Fernandes F, Ianni BM, Mady C, Ramires JA, Kalil-Filho R, Rochitte CE.

J Cardiovasc Magn Reson. 2016 Nov 28;18(1):88.

8.

Estimating the Burden of Chagas Disease in the United States.

Manne-Goehler J, Umeh CA, Montgomery SP, Wirtz VJ.

PLoS Negl Trop Dis. 2016 Nov 7;10(11):e0005033. doi: 10.1371/journal.pntd.0005033. eCollection 2016 Nov.

9.

Chagas Cardiomyopathy in New Orleans and the Southeastern United States.

Hsu RC, Burak J, Tiwari S, Chakraborti C, Sander GE.

Ochsner J. 2016 Fall;16(3):304-8.

10.

Systematic Review and Meta-analysis of the Pharmacokinetics of Benznidazole in the Treatment of Chagas Disease.

Wiens MO, Kanters S, Mills E, Peregrina Lucano AA, Gold S, Ayers D, Ferrero L, Krolewiecki A.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7035-7042. Print 2016 Dec.

PMID:
27550362
11.

Congenital Chagas' disease transmission in the United States: Diagnosis in adulthood.

Murillo J, Bofill LM, Bolivar H, Torres-Viera C, Urbina JA, Benhayon D, Torres JR.

IDCases. 2016 Aug 2;5:72-5. doi: 10.1016/j.idcr.2016.07.011. eCollection 2016.

12.

Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States.

Forsyth CJ, Hernandez S, Olmedo W, Abuhamidah A, Traina MI, Sanchez DR, Soverow J, Meymandi SK.

Clin Infect Dis. 2016 Oct 15;63(8):1056-62. doi: 10.1093/cid/ciw477. Epub 2016 Jul 17.

13.

Temporizin and Temporizin-1 Peptides as Novel Candidates for Eliminating Trypanosoma cruzi.

Souza AL, Faria RX, Calabrese KS, Hardoim DJ, Taniwaki N, Alves LA, De Simone SG.

PLoS One. 2016 Jul 6;11(7):e0157673. doi: 10.1371/journal.pone.0157673. eCollection 2016.

14.

Treatment Success in Trypanosoma cruzi Infection Is Predicted by Early Changes in Serially Monitored Parasite-Specific T and B Cell Responses.

Alvarez MG, Bertocchi GL, Cooley G, Albareda MC, Viotti R, Perez-Mazliah DE, Lococo B, Castro Eiro M, Laucella SA, Tarleton RL.

PLoS Negl Trop Dis. 2016 Apr 29;10(4):e0004657. doi: 10.1371/journal.pntd.0004657. eCollection 2016 Apr.

15.

Repurposing strategies for tropical disease drug discovery.

Klug DM, Gelb MH, Pollastri MP.

Bioorg Med Chem Lett. 2016 Jun 1;26(11):2569-76. doi: 10.1016/j.bmcl.2016.03.103. Epub 2016 Mar 30. Review.

PMID:
27080183
16.

The Trypanosoma cruzi Diamine Transporter Is Essential for Robust Infection of Mammalian Cells.

Hasne MP, Soysa R, Ullman B.

PLoS One. 2016 Apr 6;11(4):e0152715. doi: 10.1371/journal.pone.0152715. eCollection 2016.

17.

Anti-parasitic Peptides from Arthropods and their Application in Drug Therapy.

Lacerda AF, Pelegrini PB, de Oliveira DM, Vasconcelos ÉA, Grossi-de-Sá MF.

Front Microbiol. 2016 Feb 5;7:91. doi: 10.3389/fmicb.2016.00091. eCollection 2016. Review.

18.

A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease.

Barry MA, Wang Q, Jones KM, Heffernan MJ, Buhaya MH, Beaumier CM, Keegan BP, Zhan B, Dumonteil E, Bottazzi ME, Hotez PJ.

Hum Vaccin Immunother. 2016 Apr 2;12(4):976-87. doi: 10.1080/21645515.2015.1119346. Epub 2016 Feb 18.

19.

Commercial enzyme-linked immunosorbent assay versuspolymerase chain reaction for the diagnosis of chronic Chagas disease: a systematic review and meta-analysis.

Brasil PE, Castro R, Castro Ld.

Mem Inst Oswaldo Cruz. 2016 Jan;111(1):1-19. doi: 10.1590/0074-02760150296. Review.

20.

Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response.

Pinazo MJ, Posada Ede J, Izquierdo L, Tassies D, Marques AF, de Lazzari E, Aldasoro E, Muñoz J, Abras A, Tebar S, Gallego M, de Almeida IC, Reverter JC, Gascon J.

PLoS Negl Trop Dis. 2016 Jan 4;10(1):e0004269. doi: 10.1371/journal.pntd.0004269. eCollection 2016 Jan.

Supplemental Content

Support Center